Improved survival for anatomic total shoulder prostheses

Results of 4,173 shoulder arthroplasties reported to the Norwegian Arthroplasty Register from 1994 through 2012

Bjørg T S FEVANG¹,²,³, Tone W NYSTAD¹,³, Arne SKREDERSTUEN³, Ove N FURNES³,⁴, and Leif I HAVELIN³,⁴

¹ Department of Rheumatology, Haukeland University Hospital; ² Department of Clinical Science, University of Bergen; ³ The Norwegian Arthroplasty Register, Department of Orthopaedic Surgery, Haukeland University Hospital; ⁴ Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Correspondence: bjorg.tilde.svanes.fevang@helse-bergen.no
Submitted 2014-05-22. Accepted 2014-09-11.

Open Access - This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. DOI 10.3109/17453674.2014.984113

Background and purpose — Previously, implant survival of total shoulder prostheses was reported to be inferior to that of hemiprostheses. However, the use of total prostheses has increased in Norway due to reported good functional results. On this background, we wanted to study implant survival of 4 major shoulder prosthesis types in Norway between 1994 and 2012.

Patients and methods — The study population comprised 4,173 patients with shoulder replacements reported to the Norwegian Arthroplasty Register, including 2,447 hemiprostheses (HPs), 444 anatomic total prostheses (ATPs), 454 resurfacing prostheses (RPs), and 828 reversed total prostheses (RTPs). Three time periods were compared: 1994–1999, 2000–2005, and 2006–2012. Kaplan-Meier failure curves were used to compare implant failure rates for subgroups of patients, and adjusted risks of revision were calculated using Cox regression analysis.

Results — For prostheses inserted from 2006 through 2012, the 5-year survival rates were 95% for HPs (as opposed to 94% in 1994–1999), 95% for ATPs (75% in 1994–1999), 87% for RPs (96% in 1994–1999), and 93% for RTPs (91% in 1994–1999). During the study period, the implant survival improved significantly for ATPs (p < 0.001). A tendency of better results with acute fracture and worse results in sequelae after previous fractures was seen in all time periods.

Interpretation — The 5-year implant survival rates were good with all prosthesis types, and markedly improved for anatomic total prostheses in the last 2 study periods. The better functional results with total shoulder prostheses than with hemiprostheses support the trend towards increased use of total shoulder prostheses.

In a previous study from the Norwegian Arthroplasty Register (NAR), we reported superior results in terms of prosthesis survival with shoulder hemiprostheses (HPs) than with total prostheses (TPs), both anatomic and reverse (Fevang et al. 2009). However, several other studies have shown better functional results with the use of TPs than with HPs (Bryant et al. 2005, Pfahler et al. 2006, Radnay et al. 2007), and in a recent report from the NAR in which functional outcome was evaluated, patients with HPs came out worst for all variables measured (Fevang et al. 2013). Based on these studies and treatment practice in other countries, a change in treatment policy has taken place in Norway—towards reduced use of HPs and increasing use of TPs, both anatomic and reversed types. The increasing volume of shoulder arthroplasty surgery in general, and also the relative increase in the use of TPs compared to HPs, will undoubtedly have increased the experience of Norwegian surgeons with shoulder arthroplasty surgery in general and insertion of TPs in particular. With this background, we wanted to compare the results of shoulder arthroplasties in Norway over 3 time periods (1994–1999, 2000–2005, and 2006–2012) in order to determine whether this change in treatment policy has improved results in terms of prosthesis survival for total prostheses.

Patients and methods

The NAR started collection of data on shoulder prostheses in 1994. All Norwegian hospitals performing shoulder arthroplasty surgery report to the registry and the completeness of the data is good (Espehaug et al. 2006). Surgeons report primary
operations and revisions, and the form filled in by the operating surgeon contains information on patient characteristics, diagnosis, and data regarding the surgery and implant. Data on death or emigration are obtained from Statistics Norway. More than 1 diagnosis may be recorded for each patient, but for the present study, each patient was allocated 1 diagnosis according to a system in which the diagnoses were ranked as follows: osteoarthritis (OA) which ranked lowest, rheumatoid arthritis (RA), fracture sequelae (FS), and acute fracture (AF) which ranked highest. The outcome in this study was prosthesi

As the aim of this study was to compare the results of 4 major prosthesis categories within 3 time periods, only patients with the 4 most frequent diagnoses (OA, RA, FS, and AF) were included in order to obtain comparable homogenous patient groups. Patients in whom the shoulder arthroplasty was inserted due to a malignant tumor were excluded (n = 19). Furthermore, 346 patients with the following diagnoses were excluded: rotator cuff arthropathy (n = 109), sequela after ligament damage (n = 39), sequela after dislocation (n = 21), psoriatic arthritis (33), ankylosing spondylitis (21), osteonecrosis (n = 24), sequela after infection (n = 19), and other diagnosis (n = 80). Additionally, 83 patients were excluded because of missing values for one of the crucial variables (patient characteristics, date of surgery, type of prosthesis, or outcome). Eventually, 4,173 patients (3,166 women (76%) and 1,007 men (24%)) remained for inclusion, 1,398 with OA, 811 with RA, 787 with FS, and 1,177 with AF.

Patients were followed from their primary arthroplasty until revision, death, emigration, or end of follow-up (December 31, 2012). In order to study a possible change in results according to change in treatment policy, the patients were divided into 3 groups according to the year of primary surgery: 1994–1999, 2000–2005, and 2006–2012 (Table 1). Furthermore, they were grouped according to prosthesis type: hemiprostheses (HPs), anatomic total prostheses (ATPs), resurfacing prostheses (RPs), and reversed total prostheses (RTPs). The outcome in this study was prosthesi

Statistics

We used unadjusted Kaplan-Meier failure plots to illustrate differences in prosthesis failure between patients operated during the 3 different time periods for each of 4 different prosthesis types (Figure 2). Cumulative failure between the prosthesis types within 1 of 3 given time periods was compared (Figure 3) and plots according to mode of fixation were estimated for each prosthesis type (Figure 4). Since the prosthesis brands differed to some extent between the 3 study periods, separate analyses were performed comparing the most commonly used brands of each prosthesis type (Figure 5).

We used Cox regression to analyze the risk of revision for the total study period (Table 4) and within 3 different time periods, with adjustment for age, sex, diagnosis, and prosthesis type (Table 5). Method of fixation (cemented, uncemented, or hybrid) was not included in the regression analysis, as the impact of this variable is different for each prosthesis type. Instead, Kaplan-Meier failure plots illustrating the impact of fixation are presented (Figure 4). For RTPs, only patients with uncemented or hybrid fixation were included in the analysis because the number of cemented RTPs was low (n = 35).
Results

During the study period, there was a change in treatment policy in Norway from almost exclusive use of hemiprostheses to increasing use of anatomic and reverse total prostheses (Figure 1). This development was seen in patients with all 4 major diagnoses, but to a lesser degree in patients with AF (Table 2).

For patients with RA or fracture sequelae, the use of RTPs in particular increased, while for those with osteoarthritis, an increasing use of ATPs was seen. For HPs and RTPs, there was an increase in patient age at the time of surgery, but this was not seen for ATPs and RPs (Table 1). Prosthesis fixation also changed, with increasing use of cementation for HPs and ATPs. For the RTPs, a change took place from almost exclusive use of uncemented fixation during the first time period to mostly hybrid fixation in the last time period (Table 1). The cemented Scan prosthesis was the only resurfacing prosthesis used in 1994–1999. After this, the use of Scan prostheses ceased and the new RPs were uncemented (Table 1).

**Prosthesis survival**

When we analyzed all the prosthesis types together, the prosthesis survival remained unchanged during the study period (Table 3). Also, in the overall study period, those patients with AF had the lowest risk of revision, RA and OA patients had similar results, while FS patients had a 1.5 times higher risk of revision than OA patients (p = 0.008) (Table 3). Furthermore, in the overall analysis RPs and RTPs had worse results than HPs and ATPs, which had similar results (Table 3).

For prostheses inserted in the period 1994–1999, the 5-year cumulative survival rate for HPs was 94%; that for ATPs was 75%, that for RPs was 96%, and that for RTPs was 91%. The 5-year survival figures were as follows for prostheses inserted in the period 2006–2012: 95% for HPs, 95% for ATPs, 87% for RPs, and 93% for RTPs.

During the study period, a trend of improvement in results was seen for HPs (Figure 2) while the prosthesis survival improved markedly for ATPs (p < 0.001) (Figure 2). A trend of increased prosthesis failure was seen for RPs (Figure 2), while no significant change in prosthesis failure was detected for RTPs (Figure 2).
When comparing results for the 4 prosthesis types within each time period, the cumulative failure rate was much higher for ATPs than for the other prosthesis types in 1994–1999 (p < 0.001) (Figure 3). For the period 2000–2005 (Figure 3), there was no difference in prosthesis failure, while for prostheses inserted in 2006–2012, the RPs fared significantly worse (p < 0.001) (Figure 3). Similarly, in the adjusted analyses (Table 5) (p < 0.001 for comparison of causes of revision between the prosthesis types).

Furthermore, factors that had an impact on prosthesis failure changed throughout the study period (Table 4). Patients aged 70 years or more had a lower rate of revision than the younger age group in 1994–1999 and 2000–2005 (RR = 0.6 and 0.45, respectively), but in the last time period the trend was simi-
but not statistically significant (RR = 0.7 for the older age group compared to the younger one; p = 0.1) (Table 4). A tendency of better prognosis in acute fracture (AF) patients and worse prognosis in patients with sequelae after previous fractures (FS) was seen in all time periods, but was only statistically significant for patients with AF in 2000–2005 and for patients with fracture sequelae in the last time period (2006–2012) (Table 4).

In patients with HPs, the best results were seen when the prostheses were cemented (Figure 4). This was seen for HPs in all 3 time periods, but it was statistically significant only in the last 2 periods (p = 0.07, 0.01, and 0.005 for 1994–1999, 2000–2005, and 2016–2012, respectively). While there was a similar trend of worse results for uncemented prostheses in the 3 other prosthesis types (Figure 4), no statistically significant differences were seen—although RTPs with hybrid fixa-

### Table 4. Risk of revision during 3 time periods according to major explanatory factors

| Time period | Variable | Category | RR   | 95% CI  | p-value |
|-------------|----------|----------|------|---------|---------|
| 1994–1999   | Sex      | Male     | 1    |         |         |
|             |          | Female   | 0.8  | 0.5–1.4 | 0.5     |
|             |          |          |      |         |         |
|             | Age, years | 19–69   | 1    |         |         |
|             |          | ≥70      | 0.6  | 0.3–0.9 | 0.02    |
|             | Diagnosis | OA       | 1    |         |         |
|             |          | RA       | 1.0  | 0.5–2.0 | 0.9     |
|             |          | AF       | 0.5  | 0.2–1.5 | 0.2     |
|             | Prosthesis | HP     | 1    |         |         |
|             |          | ATP      | 4.5  | 2.3–9.0 | < 0.001 |
|             |          | RP       | 1.2  | 0.5–2.8 | 0.7     |
|             |          | RTP      | 2.4  | 1.4–4.1 | 0.002   |
| 2000–2005   | Sex      | Male     | 1    |         |         |
|             |          | Female   | 0.9  | 0.6–1.5 | 0.8     |
|             | Age, years | 19–69   | 1    |         |         |
|             |          | ≥70      | 0.45 | 0.3–0.7 | 0.001   |
|             | Diagnosis | OA       | 1    |         |         |
|             |          | RA       | 0.7  | 0.4–1.2 | 0.2     |
|             |          | AF       | 0.4  | 0.2–0.8 | 0.008   |
|             | Prosthesis | HP     | 1    |         |         |
|             |          | ATP      | 1.0  | 0.3–2.8 | 1.0     |
|             |          | RP       | 1.3  | 0.7–2.2 | 0.5     |
|             |          | RTP      | 1.2  | 0.6–2.2 | 0.6     |
| 2006–2012   | Sex      | Male     | 1    |         |         |
|             |          | Female   | 0.7  | 0.5–0.99| 0.05    |
|             | Age, years | 19–69   | 1    |         |         |
|             |          | ≥70      | 0.7  | 0.5–1.1 | 0.1     |
|             | Diagnosis | OA       | 1    |         |         |
|             |          | RA       | 1.0  | 0.6–1.8 | 0.9     |
|             |          | AF       | 0.6  | 0.3–1.2 | 0.2     |
|             | Prosthesis | HP     | 1    |         |         |
|             |          | ATP      | 1.0  | 0.5–1.9 | 1.0     |
|             |          | RP       | 2.4  | 1.4–4.1 | 0.001   |
|             |          | RTP      | 1.7  | 1.0–2.8 | 0.03    |

For abbreviations, see Table 3.

Impact of prosthesis brand

To investigate whether the differences in results were due to prosthesis brands that were particularly superior, separate analyses were performed for the most commonly used brands of each prosthesis type (Figure 5). There was no great difference in survival for the 5 most commonly used hemiprostheses, but better results were seen with the most recently used ATPs, Aequalis and Global (p < 0.001), than with brands used in the earlier periods. A separate analysis comparing only prostheses inserted from 2002 and later revealed the same, with statistically significantly better results for the Aequalis and Global than for the Bio-Modular (analysis not shown), and the use of the Bio-Modular had almost ceased in the last study period (only 6 cases). No significant differences were seen for the most common resurfacing prosthesis brands and reversed prosthesis brands (Figure 5C and D).

Discussion

The main finding of this study was a marked improvement in prosthesis survival for anatomic total shoulder prostheses. A change towards older patients and more cemented prostheses may partly explain this improvement. Furthermore, new prosthesis types that were used in the last 2 study periods gave markedly better results. However, the improved results may also have been caused by a positive learning curve among the operating surgeons performing more ATPs in general. This finding contrasts that of our previous article evaluating shoul-
der prosthesis survival, where failure rates of total prostheses were found to be high (Fevang et al. 2009). Cochrane reviews (Bryant et al. 2005, Singh et al. 2010) and reports from our own studies (Fevang et al. 2012, Fevang et al. 2013) showing superior functional results with ATPs may have contributed to the increasing use of such prostheses in Norway. This has most likely resulted in improvements in surgical experience and skills with these prostheses, ultimately leading to improved implant survival.

A marked change in mode of fixation from 31% to 65% cementation was seen for ATPs. Although we were unable to detect a statistically significant effect of fixation type on survival of ATPs, even in the sub-analyses for each time period, it is noteworthy that the change in type of fixation coincided with the improvement in survival results.

The Aequalis and Global ATPs gave better results than the 2 other most frequently used ATP brands in the study. This could be due to frequent use (n = 192 for Aequalis as compared to 42 for Bio-Modular) and consequent improved surgical experience with the prostheses, or it could be due to superior implant quality. The use of these prostheses in the last study period may have contributed to the increased survival of ATPs in that study period.

In a study of patients who were operated from 1995 through 2005, no statistically significant difference in implant survival rate was seen between total prostheses and hemiprostheses (Farnag et al. 2011). The 5-year implant survival for both TPs and HPs was around 93% in that study, closely resembling the values in our study (94% for HPs and 92% for ATPs) (Table 4). Furthermore, the 5-year survival of ATPs during our last study period (95%) compares well with that reported by Singh et al. (2011), although their 10-year estimate (90%) was better than the overall 10-year survival in our study (87%) (Table 4).

Destruction of the glenohumeral joint is often accompanied by rotator cuff damage in patients with RA. In such patients, the insertion of ATPs or HPs is often followed by secondary rotator cuff failure and subsequent proximal humeral migration (Sneppen et al. 1996, Stewart and Kelly 1997, Betts et al. 2009). Thus, in these patients, ATPs have not been shown to give better functional results than hemiprostheses (Trail and Nuttall 2002, Sperling et al. 2007). However, good results with the use of RTPs have been demonstrated in RA patients (Holcomb et al. 2010, John et al. 2010, Eklund and Nyberg 2011, Young et al. 2011) and we recently found that reversed prostheses resulted in less pain and better function than anatomic total prostheses and hemiprostheses in RA patients (Fevang et al. 2013). In accordance with these publications, we found a marked increase in the use of RTPs in patients with RA in the present study.

The implant failure rate was somewhat higher for RTPs than for HPs in the first and last study periods (Table 5). One reason for the higher failure rate with RTPs may be that they might have been selected for patients with shoulders that were particularly badly damaged. Adjusting for diagnosis in the regression analysis may only control for this to some extent, as these prostheses are used in patients with injured rotator cuffs, irrespective of diagnosis. Even among patients with OA an increasing use of RTPs was seen, probably comprising OA patients with particularly ruined shoulders. Rotator cuff disease has previously been shown to be a risk factor for revision after total shoulder arthroplasty (Singh et al. 2011). In addition, RTPs inserted in our last study period had excellent 5-year results, particularly the Delta Xtend, but as RTPs have previously had inferior long-term results, these new prosthesis types must be followed up further. Taking into account the probably worse preoperative status of RTP shoulders and the
good functional results, there appears to be good reasons to continue the use of RTPs in the right patients—mainly RA and FS patients with rotator cuff damage—in whom good functional results using RTP have been demonstrated (Fevang et al. 2013).

Failure rates for resurfacing prostheses appeared to be higher in the last study period (Figure 2), and compared to HPs the difference in revision risk increased (RR = 2.4 for RPs vs. HPs in the last study period). Although 48 patients had an RP inserted in the last study period, the year-by-year figure shows a fall in the use of these prostheses after 2006 (Figure 1). One explanation for the worsening of results for this prosthesis type may therefore be decreasing volume per surgeon as other and better prosthesis types are increasingly preferred.

The results for hemiprostheses in terms of implant survival were good during the whole study period. Even so, inferior results for pain and function have been demonstrated in patients with HPs, and the high rate of revisions due to pain shown in this study reflects the same problem. With the improved implant survival of ATPs shown in the last 7-year period, we expect that the use of HPs will continue to fall and that more ATPs will be used.
Radnay C S, Setter K J, Chambers L, Levine W N, Bigliani L U, Ahmad C S. Total shoulder replacement compared with humeral head replacement for the treatment of primary glenohumeral osteoarthritis: a systematic review. J Shoulder Elbow Surg 2007; 16(4): 396-402.

Singh J A, Sperling J, Buchbinder R, McMaken K. Surgery for shoulder osteoarthritis. Cochrane Database Syst Rev 2010; (10): CD008089.

Singh J A, Sperling J W, Cofield R H. Revision surgery following total shoulder arthroplasty: analysis of 2588 shoulders over three decades (1976 to 2008). J Bone Joint Surg Br 2011; 93(11): 1513-7.

Sneppen O, Fruensgaard S, Johannsen H V, Olsen B S, Sojbjerg J O, Andersen N H. Total shoulder replacement in rheumatoid arthritis: proximal migration and loosening. J Shoulder Elbow Surg 1996; 5(1): 47-52.

Sperling J W, Cofield R H, Schleck C D, Harmsen W S. Total shoulder arthroplasty versus hemiarthroplasty for rheumatoid arthritis of the shoulder: results of 303 consecutive cases. J Shoulder Elbow Surg 2007; 16(6): 683-90.

Stewart M P, Kelly I G. Total shoulder replacement in rheumatoid disease: 7- to 13-year follow-up of 37 joints. J Bone Joint Surg Br 1997; 79(1): 68-72.

Trail I A, Nuttall D. The results of shoulder arthroplasty in patients with rheumatoid arthritis. J Bone Joint Surg Br 2002; 84(8): 1121-5.

Young A A, Smith M M, Bacle G, Moraga C, Walch G. Early results of reverse shoulder arthroplasty in patients with rheumatoid arthritis. J Bone Joint Surg Am 2011; 93(20): 1915-23.